Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Single-Arm Phase I/II Clinical Study to Evaluate the Safety and Efficacy of a Single Dose of MDN-001 Injection in Patients With Unresectable Primary Hepatocellular Carcinoma (HCC).

NCT07391839 is registered in ClinicalTrials.gov with Suzhou Mednovo Yi Medical Technology Co., Ltd. as lead sponsor.

NCT NCT07391839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07391839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Single-Arm Phase I/II Clinical Study to Evaluate the Safety and Efficacy of a Single Dose of MDN-001 Injection in Patients With Unresectable Primary Hepatocellular Carcinoma (HCC).
Lead sponsor
Suzhou Mednovo Yi Medical Technology Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
August 4, 2025
Completion date
May 31, 2027
Enrollment
40 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hepatoma, unresectable hepatocellular carcinoma (hcc)